揭开 MGMT 的神秘面纱:对神经内分泌肿瘤的影响。

IF 9.7 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-18 DOI:10.1016/j.bbcan.2024.189184
{"title":"揭开 MGMT 的神秘面纱:对神经内分泌肿瘤的影响。","authors":"","doi":"10.1016/j.bbcan.2024.189184","DOIUrl":null,"url":null,"abstract":"<div><div>Neuroendocrine tumors (NETs) are a diverse group of tumors that arise from neuroendocrine cells and are commonly found in various organs. A considerable proportion of NET patients were diagnosed at an advanced or metastatic stage. Alkylating agents are the primary treatment for NET, and O<sup>6</sup>-methylguanine methyltransferase (<em>MGMT</em>) remains the first-line of defense against DNA damage caused by these agents. Clinical trials have indicated that <em>MGMT</em> promoter methylation or its low/lacked expression can predict a favorable outcome with Temozolomide in NETs. Its status could help select NET patients who can benefit from alkylating agents. Therefore, <em>MGMT</em> status serves as a biomarker to guide decisions on the efficacy of Temozolomide as a personalized treatment option. Additionally, delving into the regulatory mechanisms of <em>MGMT</em> status can lead to the development of <em>MGMT</em>-targeted therapies, benefiting individuals with high levels of <em>MGMT</em> expression. This review aims to explore the polymorphism of <em>MGMT</em> regulation and summarize its clinical implications in NETs, which would help establish the role of <em>MGMT</em> as a biomarker and its potential as a therapeutic target in NETs. Additionally, we explore the benefits of combining Temozolomide and immunotherapy in <em>MGMT</em> hypermethylated subgroups. Future studies can focus on optimizing Temozolomide administration to induce specific immunomodulatory changes.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":9.7000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors\",\"authors\":\"\",\"doi\":\"10.1016/j.bbcan.2024.189184\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Neuroendocrine tumors (NETs) are a diverse group of tumors that arise from neuroendocrine cells and are commonly found in various organs. A considerable proportion of NET patients were diagnosed at an advanced or metastatic stage. Alkylating agents are the primary treatment for NET, and O<sup>6</sup>-methylguanine methyltransferase (<em>MGMT</em>) remains the first-line of defense against DNA damage caused by these agents. Clinical trials have indicated that <em>MGMT</em> promoter methylation or its low/lacked expression can predict a favorable outcome with Temozolomide in NETs. Its status could help select NET patients who can benefit from alkylating agents. Therefore, <em>MGMT</em> status serves as a biomarker to guide decisions on the efficacy of Temozolomide as a personalized treatment option. Additionally, delving into the regulatory mechanisms of <em>MGMT</em> status can lead to the development of <em>MGMT</em>-targeted therapies, benefiting individuals with high levels of <em>MGMT</em> expression. This review aims to explore the polymorphism of <em>MGMT</em> regulation and summarize its clinical implications in NETs, which would help establish the role of <em>MGMT</em> as a biomarker and its potential as a therapeutic target in NETs. Additionally, we explore the benefits of combining Temozolomide and immunotherapy in <em>MGMT</em> hypermethylated subgroups. Future studies can focus on optimizing Temozolomide administration to induce specific immunomodulatory changes.</div></div>\",\"PeriodicalId\":8782,\"journal\":{\"name\":\"Biochimica et biophysica acta. Reviews on cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":9.7000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochimica et biophysica acta. Reviews on cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304419X2400115X\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Reviews on cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304419X2400115X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

神经内分泌肿瘤(NET)是一类由神经内分泌细胞引起的多种肿瘤,常见于各种器官。相当一部分NET患者被诊断为晚期或转移期。烷化剂是治疗 NET 的主要药物,而 O6-甲基鸟嘌呤甲基转移酶(MGMT)仍然是抵御这些药物造成的 DNA 损伤的第一道防线。临床试验表明,MGMT 启动子甲基化或其低/缺乏表达可预测替莫唑胺治疗 NET 的良好疗效。它的状态有助于筛选出能从烷化剂中获益的 NET 患者。因此,MGMT 状态可作为一种生物标志物,指导替莫唑胺作为一种个性化治疗方案的疗效决策。此外,深入研究 MGMT 状态的调控机制可以开发 MGMT 靶向疗法,使高水平 MGMT 表达的个体受益。本综述旨在探讨MGMT调控的多态性并总结其在NET中的临床意义,这将有助于确立MGMT作为生物标志物的作用及其作为NET治疗靶点的潜力。此外,我们还探讨了在MGMT高甲基化亚组中联合使用替莫唑胺和免疫疗法的益处。未来的研究可侧重于优化替莫唑胺的用药,以诱导特定的免疫调节变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors
Neuroendocrine tumors (NETs) are a diverse group of tumors that arise from neuroendocrine cells and are commonly found in various organs. A considerable proportion of NET patients were diagnosed at an advanced or metastatic stage. Alkylating agents are the primary treatment for NET, and O6-methylguanine methyltransferase (MGMT) remains the first-line of defense against DNA damage caused by these agents. Clinical trials have indicated that MGMT promoter methylation or its low/lacked expression can predict a favorable outcome with Temozolomide in NETs. Its status could help select NET patients who can benefit from alkylating agents. Therefore, MGMT status serves as a biomarker to guide decisions on the efficacy of Temozolomide as a personalized treatment option. Additionally, delving into the regulatory mechanisms of MGMT status can lead to the development of MGMT-targeted therapies, benefiting individuals with high levels of MGMT expression. This review aims to explore the polymorphism of MGMT regulation and summarize its clinical implications in NETs, which would help establish the role of MGMT as a biomarker and its potential as a therapeutic target in NETs. Additionally, we explore the benefits of combining Temozolomide and immunotherapy in MGMT hypermethylated subgroups. Future studies can focus on optimizing Temozolomide administration to induce specific immunomodulatory changes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biochimica et biophysica acta. Reviews on cancer
Biochimica et biophysica acta. Reviews on cancer 医学-生化与分子生物学
CiteScore
17.20
自引率
0.00%
发文量
138
审稿时长
33 days
期刊介绍: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer encompasses the entirety of cancer biology and biochemistry, emphasizing oncogenes and tumor suppressor genes, growth-related cell cycle control signaling, carcinogenesis mechanisms, cell transformation, immunologic control mechanisms, genetics of human (mammalian) cancer, control of cell proliferation, genetic and molecular control of organismic development, rational anti-tumor drug design. It publishes mini-reviews and full reviews.
期刊最新文献
Roles of K(H)SRP in modulating gene transcription throughout cancer progression: Insights from cellular studies to clinical perspectives The curious case of type I interferon signaling in cancer Decoding secret role of mesenchymal stem cells in regulating cancer stem cells and drug resistance Methyltransferases in cancer drug resistance: Unlocking the potential of targeting SMYD3 to sensitize cancer cells Dual roles of human endogenous retroviruses in cancer progression and antitumor immune response
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1